InflaRx NV
NASDAQ:IFRX
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
DE |
InflaRx NV
NASDAQ:IFRX
|
86m USD | 6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
274.3B USD | 8.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
161B USD | 10.8 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.4B USD | 11.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.2B USD | 8.8 | ||
AU |
CSL Ltd
ASX:CSL
|
135.6B AUD | 13.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.7B USD | 4.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
58.7B USD | 43.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.8B USD | 5.1 | ||
KR |
Celltrion Inc
KRX:068270
|
36.9T KRW | 34.6 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.